Table 2.
Compliance with the AAAAI guidelines for diagnostic vaccination.
| Case patients | Control patients | All patients, | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LRTI, n = 114 | URTI, n = 28 | Abscesses, n = 39 | Viral, n = 27 | Fungal, n = 6 | Invasive bacterial, n = 5 | Other, n = 10 | n = 229 | ||||||||||||
| Failed initiation (serotype-specific antibodies not measured), n (%) | 6 | (5.3) | 1 | (3.6) | 13 | (33) | 16 | (59) | 2 | (33) | 4 | (80) | 5 | (50) | 47 | (21) | |||
| Failed procedure, n (%) | 86 | (75) | 20 | (71) | 20 | (51) | 9 | (33) | 3 | (50) | 1 | (20) | 4 | (40) | 143 | (62) | |||
| Serotype-specific antibody measurements: | |||||||||||||||||||
| Never quantitative | 22 | (19) | 1 | (3.6) | 3 | (7.7) | 7 | (26) | 1 | (17) | 0 | 1 | (10) | 35 | (15) | ||||
| Lacking before vaccination | 16 | (14) | 6 | (21) | 3 | (7.7) | 0 | 0 | 0 | 1 | (10) | 26 | (11) | ||||||
| Only qualitatively before vaccination | 5 | (4.4) | 2 | (7.1) | 1 | (2.6) | 0 | 0 | 1 | (20) | 2 | (20) | 11 | (4.8) | |||||
| Natural immunity inadequate but: | |||||||||||||||||||
| PPV not administered | 14 | (12) | 9 | (32) | 9 | (23) | 2 | (7.4) | 2 | (33) | 0 | 0 | 36 | (16) | |||||
| PPV administered but follow-up antibody measurements: | |||||||||||||||||||
| Lacking | 4 | (3.5) | 1 | (3.6) | 1 | (2.6) | 0 | 0 | 0 | 0 | 6 | (2.6) | |||||||
| Qualitative | 14 | (12) | 0 | 1 | (2.6) | 0 | 0 | 0 | 0 | 15 | (6.6) | ||||||||
| Quantitative but before week 4 | 1 | (0.88) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | (0.44) | |||||||||
| Quantitative but after week 8 | 7 | (6.1) | 0 | 1 | (2.6) | 0 | 0 | 0 | 0 | 8 | (3.5) | ||||||||
| Date of PPV vaccination uncertain | 3 | (2.6) | 0 | 0 | 0 | 0 | 0 | 0 | 3 | (1.3) | |||||||||
| Previous administered conjugate pneumococcal vaccine | 0 | 1 | (3.6) | 1 | (2.6) | 0 | 0 | 0 | 0 | 2 | (0.87) | ||||||||
| Completed procedure, n (%) | 22 | (19) | 7 | (25) | 6 | (15) | 2 | (7.4) | 1 | (17) | 0 | 1 | (10) | 39 | (17) | ||||
| Adequate natural immunity, PPV not administered | 1 | (0.9) | 2 | (7.1) | 3 | (7.7) | 1 | (3.7) | 1 | (17) | 0 | 0 | 8 | (3.5) | |||||
| Adequate natural immunity, PPV administered (superfluous) | 0 | 1 | (3.6) | 0 | 1 | (3.7) | 0 | 0 | 0 | 2 | (0.87) | ||||||||
| Inadequate natural immunity, PPV administered and follow-up with quantitative antibody measurements |
21 | (18) | 4 | (14) | 3 | (7.7) | 0 | 0 | 0 | 1 | (10) | 29 | (13) | ||||||
Each participant was assigned to the first correct category in the left column (top-to-bottom). Adequate natural immunity was defined as ≥ 70% of measured levels of serotype-specific antibodies ≥ 1.3 mg/L.
Categories of compliance are indicated in bold.